【24h】

Left atrial appendage closure: Does 'leak' matter?

机译:左心耳封堵:“渗漏”重要吗?

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Aim: To determine the safety and effectiveness of insulin analogues in type 2 diabetes (T2D) patients in the Algerian cohort of the A1chieve study and to examine the status of T2D management across different regions in Algeria. Methods: Patients starting therapy with biphasic insulin aspart 30, insulin detemir, insulin aspart (IAsp) or IAsp + basal insulin at their physicians' decision were included. The primary outcome was the incidence of serious adverse drug reactions (SADRs), including major hypoglycaemia. Secondary outcomes included changes from baseline to Week 24 in hypoglycaemia, glycated haemoglobin A1c (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPPG), weight and quality of life (QoL, evaluated using the EQ-5D questionnaire). Results: Overall, 1494 patients (mean±SD age: 60.1±10.3 years; body mass index: 28.1±4.9kg/m2; HbA1c: 9.2±1.8%) were enrolled. Poor baseline glucose control was revealed across the different Algerian regions with mean HbA1c varying from 8.9% to 9.6%. Two SADRs were reported during the study. The proportion of patients reporting major hypoglycaemic events decreased from 1.1% at baseline to 0.2% at Week 24 (p = 0.0017). Significant improvements in mean HbA1c (-1.3±2.0%), FPG (-38.8±79.9 mg/dL) and post-breakfast PPPG (-51.4±97.1 mg/dL) were observed in the entire cohort (all p 0.001). The mean body weight increased by 0.9±3.8kg, while QoL increased by 9.2±16.7 points after 24 weeks. Conclusions: Insulin analogue therapy was well-tolerated and significantly improved blood glucose control over 24 weeks in the Algerian cohort.
机译:目的:在A1chieve研究的阿尔及利亚队列中,确定2型糖尿病(T2D)患者中胰岛素类似物的安全性和有效性,并检查阿尔及利亚不同地区T2D管理的状况。方法:纳入根据医师决定开始使用双相门冬胰岛素30,地特米胰岛素,门冬胰岛素(IAsp)或IAsp +基础胰岛素治疗的患者。主要结果是严重的药物不良反应(SADR)的发生率,包括主要的低血糖症。次要结果包括从基线到第24周的低血糖,糖化血红蛋白A1c(HbA1c),空腹血糖(FPG),餐后血浆葡萄糖(PPPG),体重和生活质量(QoL,使用EQ-5D调查表评估)的变化。结果:总共入组1494例患者(平均±SD年龄:60.1±10.3岁;体重指数:28.1±4.9kg / m2; HbA1c:9.2±1.8%)。在阿尔及利亚不同地区发现基线血糖控制不良,平均HbA1c在8.9%至9.6%之间变化。研究期间报告了两个SADR。报告主要降血糖事件的患者比例从基线的1.1%降至第24周的0.2%(p = 0.0017)。在整个队列中均观察到平均HbA1c(-1.3±2.0%),FPG(-38.8±79.9 mg / dL)和早餐后PPPG(-51.4±97.1 mg / dL)的显着改善(所有p <0.001)。 24周后,平均体重增加了0.9±3.8kg,而QoL增加了9.2±16.7点。结论:在阿尔及利亚队列中,胰岛素类似疗法耐受良好,并在24周内显着改善了血糖控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号